N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Not applicable ClinicalTrials.gov

PRecision Oncology Evidence Development in Cancer Treatment - Clinical: PREDiCTc

Sponsor: British Columbia Cancer Agency • ClinicalTrials.gov ID: NCT04814095

Registry updated: 2026-10-19
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

This pilot clinical trial aims to assess the real world quality of life and survival of patients treated with targeted therapy that has preliminary evidence of efficacy in subjects with advanced rare cancers or cancer harbouring rare molecular aberrations. The treatment has been granted conditional or full approved by Health Canada (HC) as effective and safe. Due to the rarity of the cancer or molecular aberration the uncertainty level of the health technology assessment (HTA) by the pan Canadian Oncology Review (pCODR) was too high for consideration of funding or it was not submitted for consideration. Consequently, the goal of this study is to generate real world evidence to support HTA decision making throughout the life cycle of the product.

Interventions

  • QOL (Behavioral)
    QOL assessments using the ESAS, CPC, EQ5D every 4-8 weeks +/- 2 weeks
  • CT imaging (Diagnostic test)
    CT radiographic imaging every 12 weeks +/- 2 weeks

Eligibility criteria

Inclusion Criteria: * Subject age greater than or equal to 18 years at the time of signature of informed consent. * Subjects with an incurable malignancy who have been identified to have a rare cancer or rare molecular aberration who is currently receiving Health Canada approved targeted therapy that is not nationally funded * ECOG 0-2 * Life expectancy of at least 12 weeks * Adequate hematologic and end organ function for drug treatment per the clinician's assessment * Asymptomatic or treated brain metastases permitted * Ability to give informed consent for the study procedures defined in this protocol. Exclusion Criteria: * Treatment with any approved or investigational agent or participation in another clinical trial with therapeutic intent within 14 days prior to enrollment. * Inability to complete quality of life questionnaires * Subjects who are felt by the treating clinician to be unfit to proceed with this protocol.

Conditions

Cancer

Locations

  • BC Cancer — Vancouver, British Columbia, Canada
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record